← Aclaris Therapeutics, Inc. (ACRS) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aclaris Therapeutics, Inc. (ACRS)
Pharmaceutical Preparations · market cap $774M · as of 2026-07-22
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-05 (est.)
Earnings
Pipeline
19
programs
Upcoming events
1
next 90d+
Dossier
Ready
cached
Aclaris Therapeutics (ACRS) is a 61-employee dermatology-focused biotech with a $778M market cap and a broad pipeline spanning topical and systemic assets across seborrheic keratosis, atopic dermatitis, rheumatoid arthritis, alopecia, and vitiligo. The lead asset A-101 Solution is in Phase 3 for seborrheic keratosis, with multiple additional Phase 2 programs active. The company carries only $28.7M in cash, implying a roughly 4.7-month runway, creating acute near-term financing pressure.
The catalyst path
- 2026-11-05 (est.)Earningsimp 5/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ATI-1777 2.0% w/w | Phase 2 | Atopic Dermatitis |
| ATI-450 | Phase 2 | Rheumatoid Arthritis |
| A-101 Solution | Phase 3 | Seborrheic Keratosis |
| A-101 | Phase 3 | Common Wart |
| ATI-502 | Phase 2 | Atopic Dermatitis |
| ATI-045 | Phase 2 | Atopic Dermatitis |
| ATI-1777 | Phase 2 | Atopic Dermatitis |
| A-101 Vehicle | Phase 2 | Seborrheic Keratosis |
| Active | Phase 3 | Common Wart |
| A-101 Topical Solution 40% | Phase 2 | Dermatosis Papulosa Nigra |
| ATI-450 50 mg oral tablet BID | Phase 2 | Rheumatoid Arthritis |
| A-101 Topical Solution | Phase 2 | Common Wart |
| ATI-501 400mg BID (Low dose) | Phase 2 | Alopecia |
| ATI-50002 topical solution | Phase 2 | Vitiligo |
| A-101 25% | Phase 2 | Seborrheic Keratosis (SK) |
| ATI-2138 | Phase 2 | Atopic Dermatitis |
| ATI-50002 | Phase 2 | Androgenetic Alopecia |
| A-101 Vehicle Solution | Phase 2 | Common Wart |
| A-101 Solution 40 | Phase 2 | Common Warts |
Price & technical context
3-month
-20.7%
6-month
+6.5%
12-month
+132.1%
52-wk range
$1.81–$6.53
vs 50-day MA
-23.0%
vs 200-day MA
-0.7%
Realized vol
88.0%
Max drawdown
-76.5%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACRS (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 19 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.